 |
|
Non-Hodgkin Lymphoma Trial Results
1. Maintenance Rituximab May Improve Survival in Follicular Lymphoma
(Posted: 04/02/2009) - Follicular lymphoma patients who receive maintenance therapy with rituximab after their disease goes into remission may have better survival than those who do not receive such therapy, according to the February 18, 2009, issue of Journal of the National Cancer Institute.
2. Study Suggests New Options for Follicular Lymphoma
(Posted: 10/30/2008) - Treatment with a radiolabeled monoclonal antibody appears to be highly effective as consolidation after first-line therapy in patients with indolent, advanced-stage follicular lymphoma, according to the October 14, 2008, Journal of Clinical Oncology.
3. Follicular Lymphoma Treatment Better With Rituximab
(Posted: 05/15/2005, Updated: 08/18/2008) - In patients with newly diagnosed follicular lymphoma, the addition of rituximab (Rituxan®) to the standard chemotherapy regimen CVP dramatically delayed the progression of disease, produced higher response rates that lasted longer, and extended survival compared to treatment with CVP alone, according to the July 28, 2008, Journal of Clinical Oncology.
4. Less-Intense Chemotherapy Benefits Some Children With B-Cell Non-Hodgkin Lymphoma
(Posted: 04/25/2007) - Children and adolescents with less advanced B-cell non-Hodgkin lymphoma did just as well, and suffered fewer side effects, when treated with lower doses of multi-drug chemotherapy than is called for by the current standard of care, according to the April 1, 2007, issue of the journal Blood.
5. Radiation Might be Avoided for Older Patients with Good Prognosis Non-Hodgkin Lymphoma
(Posted: 02/14/2007) - Chemotherapy alone was just as effective as chemoradiotherapy in promoting survival among certain lymphoma patients over 60, suggesting that similar patients might be able to avoid the toxicity of radiation therapy, according to the March 1, 2007, Journal of Clinical Oncology.
1 2 3 Next >
|
|
|
